# Mardia Samyoung Capillary Tubes Company share price today (Mardia Samyoung Capillary Tubes Company Ltd, NSE: MSCTC)

> Mardia Samyoung Capillary Tubes Company share price today: ₹51.94 at the BSE close on 30 October 2026, down 54.5% in a year. Mardia Samyoung Capillary Tubes Company (NSE: MSCTC) trades at a P/E of 687.0 and has closed between ₹40.50 and ₹123.40 over the past 52 weeks. > Mardia Samyoung Capillary Tubes Company Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. MSCTC · Trading · data as of 30 October 2026. Page: https://www.sectoralpha.in/stocks/mardia-samyoung-capillary-tubes-company-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹51.94 (−54.5% in a year)
- P/E: 687.0×, over 9.2 years
- Revenue (Dec 2025): ₹12.3 Cr
- Profit (Dec 2025): ₹1.3 Cr
- Operating margin: 15.3%
- ROCE: 23%, FY25

Biggest thing to watch: the price has already been rising for 63 weeks, so timing is the risk more than the business. ## What is the Mardia Samyoung Capillary Tubes Company share price today? Mardia Samyoung Capillary Tubes Company Ltd's share price was ₹51.94 at the close on 30 October 2026. It has been rising for 63 weeks. That is 5.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹41 and ₹123, and at that close it sat 14% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 8 weeks in a row. Over the last 11 years the share price moved +366% while the NIFTY 500 moved +233%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Mardia Samyoung Capillary Tubes Company's latest quarterly results? For October to December 2025 (the quarter ended 31 December 2025), Mardia Samyoung Capillary Tubes Company reported revenue of ₹12.3 crore, and a profit of ₹1.29 crore, against a loss of ₹0.05 crore a year earlier. ### Mardia Samyoung Capillary Tubes Company results: October to December 2025 against a year earlier

| Measure | October to December 2025 | October to December 2024 | Change |
| --- | --- | --- | --- |
| Revenue | ₹12.3 crore | ₹0.00 crore | n/a |
| Profit | ₹1.29 crore | loss of ₹0.05 crore | n/a |
| Earnings per share | ₹1.85 | ₹−0.07 | n/a |
| Operating margin | 15.3% | n/a | n/a |

The next results, for January to March 2026, were due by 30 May 2026: listed companies must publish quarterly results within 60 days of the quarter's end (the January to March quarter comes with the full-year accounts). This page shows them once our weekly data update has read them. (From the company's reported quarterly results (quarter ended 31 December 2025). Revenue and profit in ₹ crore.)

## What is the Mardia Samyoung Capillary Tubes Company share price history? Mardia Samyoung Capillary Tubes Company closed at ₹51.94 on 30 October 2026, down 54.5% from ₹114.08 a year earlier (31 October 2025). Its highest weekly close since April 2016 was ₹123.40 on 7 November 2025. ### Mardia Samyoung Capillary Tubes Company share price: then and now

| When | Close | Change to 30 Oct 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹45.25 | +14.8% |
| 1 month ago · 1 Oct 2026 | ₹50.94 | +2.0% |
| 6 months ago · 30 Apr 2026 | ₹66.46 | −21.8% |
| 1 year ago · 31 Oct 2025 | ₹114.08 | −54.5% |
| 10 years ago · 3 Nov 2016 | ₹4.14 | +1,154.6% |
| Earliest weekly close in our records · 5 Apr 2016 | ₹11.15 | +365.8% |
| Highest weekly close since April 2016, also the 52-week high · 7 Nov 2025 | ₹123.40 | −57.9% |
| Lowest weekly close since April 2016 · 26 Nov 2020 | ₹1.80 | +2,785.6% |
| 52-week low (weekly close) · 17 Jul 2026 | ₹40.50 | +28.2% |

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes. (212 weekly closes from 5 April 2016 to 30 October 2026.)

## What is the latest news on Mardia Samyoung Capillary Tubes Company? 30 Oct 2026: Mardia Samyoung Capillary Tubes Company closed at ₹51.94, up 14.8% on the week and up 2.0% on the month. ## What dividend does Mardia Samyoung Capillary Tubes Company pay? Mardia Samyoung Capillary Tubes Company has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Mardia Samyoung Capillary Tubes Company Ltd paid out 0% of its profit as dividends in each of its last 12 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Mardia Samyoung Capillary Tubes Company on? Mardia Samyoung Capillary Tubes Company is not on any of our India lists this week. ## Is Mardia Samyoung Capillary Tubes Company profitable? Mardia Samyoung Capillary Tubes Company Ltd earned ₹1.3 Cr of net profit in the Dec 2025 quarter. Full-year FY25 profit was ₹1.2 Cr. That is 10.4% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 Cr. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Mardia Samyoung Capillary Tubes Company make, and is it growing? Mardia Samyoung Capillary Tubes Company Ltd reported ₹12.3 Cr of revenue in the Dec 2025 quarter. The last full year, FY25, came in at ₹0.0 Cr. The last four reported quarters add to ₹12.8 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. ## How much of every ₹100 of sales does Mardia Samyoung Capillary Tubes Company keep? Mardia Samyoung Capillary Tubes Company Ltd's operating margin was 15.3% in the Dec 2025 quarter. Across 5 years it has been between −150.8% and 4,000.0%. The latest quarter is within that range. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Mardia Samyoung Capillary Tubes Company's profit turning into cash? Over the last 2 years Mardia Samyoung Capillary Tubes Company Ltd's operations used more cash than they brought in, so cash conversion was −206%, a gap worth watching. In FY25 its operations used ₹2.5 Cr of cash, against ₹1.2 Cr of profit. After −₹3.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: it has been selling more assets than it buys. The next section shows those figures. ## Where does Mardia Samyoung Capillary Tubes Company's cash go? Mardia Samyoung Capillary Tubes Company Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹0.0 Cr in FY25), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. Over the last 3 years it sold more assets than it bought, by ₹2.0 Cr. Over the last 3 years, money from selling assets was ₹2.0 Cr more than it spent on new ones. Work still in progress is ₹0.0 Cr (FY25). In short: assets are being sold, not built, so this cash is not going into new capacity. ## What is Mardia Samyoung Capillary Tubes Company's P/E ratio, and how does it compare with its own history? Mardia Samyoung Capillary Tubes Company Ltd's P/E is 687.0×, with too little history to compare. Its usual P/E (the middle reading) is 307.0×, over 9.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Mardia Samyoung Capillary Tubes Company business getting better or worse? Mardia Samyoung Capillary Tubes Company Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Mardia Samyoung Capillary Tubes Company earn on its capital? Mardia Samyoung Capillary Tubes Company Ltd earned a ROCE of 23% in FY25. That is up from a low of −10% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 364.3% net margin and −0.02× asset turnover (sales divided by assets). Why the return is what it is (FY24): a 364.3% net margin × −0.02× asset turnover × 1.54× leverage (assets divided by equity) ≈ −11.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Mardia Samyoung Capillary Tubes Company have too much debt? Mardia Samyoung Capillary Tubes Company Ltd had ₹0.0 Cr of borrowings against ₹5.6 Cr of equity in FY25, so its debt is 0.00× its equity. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Over the last 3 of those years it sold more assets than it bought, by ₹2.0 Cr. The spending on assets is being paid for from cash, not new debt. ## What is the Mardia Samyoung Capillary Tubes Company shareholding pattern? No group of Mardia Samyoung Capillary Tubes Company Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.0 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +0.0 points over 8 quarters, to 69.4%; Domestic institutions: +0.0 points over 8 quarters, to 0.1%. ## How far is Mardia Samyoung Capillary Tubes Company from balance-sheet trouble? For Mardia Samyoung Capillary Tubes Company Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Mardia Samyoung Capillary Tubes Company rank in its industry? 55.3 out of 100, rank 52 of 63 in Trading, with 26% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Mardia Samyoung Capillary Tubes Company Ltd scores 55.3 out of 100 against the 63 companies it is compared with in Trading, ranking 52. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 25.4 + 19.1 + 10.8 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Mardia Samyoung Capillary Tubes Company compared with? Mardia Samyoung Capillary Tubes Company ranks 52 of 63 Trading companies on the 4-Factor Sector Score, with 55.3 out of 100. 1. [Mangalam Global Enterprise Ltd](https://www.sectoralpha.in/stocks/mangalam-global-enterprise-ltd) MGEL · turning · Most evidence points up · 93% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidence Capital efficiency 14.6/25 · ROCE 17% · Operating margin 2.3% · 100% evidence Valuation 15.8/20 · P/E 14.6× · PEG 0.31 · 65% evidence Relative strength 17.2/20 · Lead over its industry 12.9% · Lead over NIFTY 500 25.7% · 1 year 18.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.5 + 14.6 + 15.8 + 17.2 = 70.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shankara Buildpro Ltd](https://www.sectoralpha.in/stocks/shankara-buildpro-ltd) BUILDPRO · quiet · Too little evidence to rank firmly · 59% evidence 64.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/43.75 · Revenue 26.3% · Profit 41.9% · Operating margin change -0.2 points · 88% evidence Capital efficiency 21.5/31.25 · ROCE 39% · Operating margin 3.2% · 100% evidence Valuation 13.4/25 · P/E 16× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 30 + 21.5 + 13.4 = 64.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Ivalue Infosolutions Ltd](https://www.sectoralpha.in/stocks/ivalue-infosolutions-ltd) IVALUE · quiet · Evidence leans up · 74% evidence 64.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 5.4% · Profit 22.1% · Operating margin change 5.6 points · 88% evidence Capital efficiency 19.8/25 · ROCE 25.4% · Operating margin 10% · 100% evidence Valuation 15.7/20 · P/E 10× · PEG 0.43 · 65% evidence Relative strength 8.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.6% · 1 year -31.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 20.7 + 19.8 + 15.7 + 8.1 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) Too little evidence to rank firmly · 53% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit 100% · Operating margin change 0.8 points · 62% evidence Capital efficiency 16.4/25 · ROCE 23.5% · Operating margin 2.7% · 95% evidence Valuation 11.5/20 · P/E 1.2× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 136% · 1 year n/a · 25% evidence Exact sum: 23.9 + 16.4 + 11.5 + 12.4 = 64.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [Nupur Recyclers Ltd](https://www.sectoralpha.in/stocks/nupur-recyclers-ltd) NRL · leader · Evidence leans up · 78% evidence 63.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 40.6% · Profit 29.8% · Operating margin change 3.6 points · 83% evidence Capital efficiency 15.3/25 · ROCE 15.1% · Operating margin 11.6% · 76% evidence Valuation 7.6/20 · P/E 64.4× · PEG n/a · 50% evidence Relative strength 19.9/20 · Lead over its industry 86.1% · Lead over NIFTY 500 100.5% · 1 year 134.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 15.3 + 7.6 + 19.9 = 63.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Arisinfra Solutions Ltd](https://www.sectoralpha.in/stocks/arisinfra-solutions-ltd) ARIS · breaking out · Too little evidence to rank firmly · 56% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 45.3% · Profit 100% · Operating margin change 2 points · 83% evidence Capital efficiency 13.5/25 · ROCE 15.6% · Operating margin 11% · 76% evidence Valuation 10.7/20 · P/E 17.2× · PEG n/a · 15% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 16.6% · 1 year -14.9% · 25% evidence · 11 of 12 weeks ahead Exact sum: 26.5 + 13.5 + 10.7 + 10.9 = 61.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Bhatia Communications & Retail (India) Ltd](https://www.sectoralpha.in/stocks/bhatia-communications-retail-indialtd) Evidence leans up · 68% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 49% · Profit 45.5% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.4/25 · ROCE 21.3% · Operating margin 5.3% · 95% evidence Valuation 9.2/20 · P/E 22.8× · PEG n/a · 50% evidence Relative strength 11.5/20 · Lead over its industry n/a · Lead over NIFTY 500 30.1% · 1 year n/a · 25% evidence Exact sum: 21.7 + 18.4 + 9.2 + 11.5 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [DC Infotech & Communication Ltd](https://www.sectoralpha.in/stocks/dc-infotech-communication-ltd) DCI · breaking out · Evidence leans up · 81% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 29.1% · Profit 41.9% · Operating margin change 0.4 points · 88% evidence Capital efficiency 16.5/25 · ROCE 23% · Operating margin 4.8% · 100% evidence Valuation 13.4/20 · P/E 24.6× · PEG 0.82 · 100% evidence Relative strength 11.1/20 · Lead over its industry n/a · Lead over NIFTY 500 20.1% · 1 year n/a · 25% evidence · 6 of 6 weeks ahead Exact sum: 19.3 + 16.5 + 13.4 + 11.1 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [SG Mart Ltd](https://www.sectoralpha.in/stocks/sg-mart-ltd) SGMART · leader · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidence Capital efficiency 11.6/25 · ROCE 10.2% · Operating margin 4.6% · 100% evidence Valuation 7.9/20 · P/E 71.1× · PEG 1.81 · 65% evidence Relative strength 18.3/20 · Lead over its industry 47.1% · Lead over NIFTY 500 60.5% · 1 year 146.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.3 + 11.6 + 7.9 + 18.3 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) TEMBO · losing its lead · Evidence leans up · 71% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.6/35 · Revenue 34% · Profit 55.7% · Operating margin change 5 points · 83% evidence Capital efficiency 19.6/25 · ROCE 22.8% · Operating margin 16% · 76% evidence Valuation 11.2/20 · P/E 9.3× · PEG n/a · 15% evidence Relative strength 7.0/20 · Lead over its industry -19.2% · Lead over NIFTY 500 -8.7% · 1 year -20.8% · 100% evidence · 3 of 12 weeks ahead Exact sum: 21.6 + 19.6 + 11.2 + 7 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Rashi Peripherals Ltd](https://www.sectoralpha.in/stocks/rashi-peripherals-ltd) RPTECH · losing its lead · Evidence leans up · 78% evidence 59.3 out of 100 Growth Capital Valuation Relative
12. [Sudarshan Pharma Industries Ltd](https://www.sectoralpha.in/stocks/sudarshan-pharma-industries-ltd) SUDARSHAN · turning · Evidence leans up · 85% evidence 58.7 out of 100 Growth Capital Valuation Relative
13. [Singer India Ltd](https://www.sectoralpha.in/stocks/singer-india-ltd) SINGERIND · Evidence leans up · 61% evidence 58.0 out of 100 Growth Capital Valuation Relative
14. [Euro Pratik Sales Ltd](https://www.sectoralpha.in/stocks/euro-pratik-sales-ltd) EUROPRATIK · quiet · Evidence leans up · 64% evidence 57.5 out of 100 Growth Capital Valuation Relative
15. [Pramara Promotions Ltd](https://www.sectoralpha.in/stocks/pramara-promotions-ltd) PRAMARA · Too little evidence to rank firmly · 52% evidence 54.6 out of 100 Growth Capital Valuation Relative
16. [State Trading Corporation of India Ltd](https://www.sectoralpha.in/stocks/state-trading-corporation-of-india-ltd) STCINDIA · quiet · Too little evidence to rank firmly · 57% evidence 53.4 out of 100 Growth Capital Valuation Relative
17. [Patel Retail Ltd](https://www.sectoralpha.in/stocks/patel-retail-ltd) PATELRMART · turning · Evidence leans up · 64% evidence 53.2 out of 100 Growth Capital Valuation Relative
18. [Yogi Ltd](https://www.sectoralpha.in/stocks/yogi-ltd) YOGI · quiet · Evidence leans up · 64% evidence 51.2 out of 100 Growth Capital Valuation Relative
19. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) TRANSCHEM · Too little evidence to rank firmly · 52% evidence 51.0 out of 100 Growth Capital Valuation Relative
20. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) PROSTARM · breaking out · Evidence leans up · 64% evidence 50.8 out of 100 Growth Capital Valuation Relative
21. [Dhunseri Ventures Ltd](https://www.sectoralpha.in/stocks/dhunseri-ventures-ltd) DVL · breaking out · Evidence leans up · 78% evidence 50.6 out of 100 Growth Capital Valuation Relative
22. Bizotic Commercial Ltd losing its lead · Evidence leans up · 63% evidence 50.5 out of 100 Growth Capital Valuation Relative
23. BMW Ventures Ltd BMW · Too little evidence to rank firmly · 51% evidence 50.2 out of 100 Growth Capital Valuation Relative
24. [Cropster Agro Ltd](https://www.sectoralpha.in/stocks/cropster-agro-ltd) quiet · Evidence leans down · 65% evidence 49.1 out of 100 Growth Capital Valuation Relative
25. [MMTC Ltd](https://www.sectoralpha.in/stocks/mmtc-ltd) MMTC · quiet · Evidence leans down · 92% evidence 47.2 out of 100 Growth Capital Valuation Relative
26. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) SHIVAUM · breaking out · Evidence leans down · 63% evidence 46.8 out of 100 Growth Capital Valuation Relative
27. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) BPAGRI · Too little evidence to rank firmly · 51% evidence 43.8 out of 100 Growth Capital Valuation Relative
28. [Lloyds Enterprises Ltd](https://www.sectoralpha.in/stocks/lloyds-enterprises-ltd) LLOYDSENT · quiet · Evidence leans down · 71% evidence 43.1 out of 100 Growth Capital Valuation Relative
29. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) HEXATRADEX · breaking out · Evidence leans down · 64% evidence 39.9 out of 100 Growth Capital Valuation Relative
30. [Shanti Overseas (India) Ltd](https://www.sectoralpha.in/stocks/shanti-overseas-indialtd) SHANTI · Evidence leans down · 61% evidence 39.3 out of 100 Growth Capital Valuation Relative
31. [Riddhi Siddhi Gluco Biols Ltd](https://www.sectoralpha.in/stocks/riddhi-siddhi-gluco-biols-ltd) turning · Evidence leans down · 83% evidence 38.9 out of 100 Growth Capital Valuation Relative
32. [Hardwyn India Ltd](https://www.sectoralpha.in/stocks/hardwyn-india-ltd) HARDWYN · basing · Evidence leans down · 86% evidence 38.8 out of 100 Growth Capital Valuation Relative
33. [Adani Enterprises Ltd](https://www.sectoralpha.in/stocks/adani-enterprises-ltd) ADANIENT · quiet · Evidence leans down · 93% evidence 38.1 out of 100 Growth Capital Valuation Relative
34. [PTC India Ltd](https://www.sectoralpha.in/stocks/ptc-india-ltd) PTC · quiet · Evidence leans down · 78% evidence 37.4 out of 100 Growth Capital Valuation Relative
35. [Le Merite Exports Ltd](https://www.sectoralpha.in/stocks/le-merite-exports-ltd) LEMERITE · Too little evidence to rank firmly · 59% evidence 36.8 out of 100 Growth Capital Valuation Relative
36. [Fabtech Technologies Ltd](https://www.sectoralpha.in/stocks/fabtech-technologies-ltd) FABTECH · quiet · Evidence leans down · 68% evidence 36.7 out of 100 Growth Capital Valuation Relative
37. [Uniphos Enterprises Ltd](https://www.sectoralpha.in/stocks/uniphos-enterprises-ltd) UNIENTER · turning · Too little evidence to rank firmly · 59% evidence 35.7 out of 100 Growth Capital Valuation Relative
38. Manbro Industries Ltd Too little evidence to rank firmly · 57% evidence 35.3 out of 100 Growth Capital Valuation Relative
39. Shah Foods Ltd quiet · Too little evidence to rank firmly · 53% evidence 35.3 out of 100 Growth Capital Valuation Relative
40. [BN Agrochem Ltd](https://www.sectoralpha.in/stocks/bn-agrochem-ltd) BNAGROCHEM · quiet · Most evidence points down · 64% evidence 34.1 out of 100 Growth Capital Valuation Relative
41. [Neueon Corporation Ltd](https://www.sectoralpha.in/stocks/neueon-corporation-ltd) NEUEON · quiet · Too little evidence to rank firmly · 56% evidence 33.3 out of 100 Growth Capital Valuation Relative
42. [Kothari Industrial Corporation Ltd](https://www.sectoralpha.in/stocks/kothari-industrial-corporation-ltd) KOTIC · quiet · Too little evidence to rank firmly · 53% evidence 32.9 out of 100 Growth Capital Valuation Relative
43. [Oswal Agro Mills Ltd](https://www.sectoralpha.in/stocks/oswal-agro-mills-ltd) OSWALAGRO · Too little evidence to rank firmly · 52% evidence 28.6 out of 100 Growth Capital Valuation Relative
44. [Susan Electricals India Ltd](https://www.sectoralpha.in/stocks/susan-electricals-india-ltd) quiet · Too little evidence to rank firmly · 36% evidence 61.2 out of 100 Growth Capital Valuation Relative
45. [Magnus Steel & Infra Ltd](https://www.sectoralpha.in/stocks/magnus-steel-infra-ltd) Too little evidence to rank firmly · 40% evidence 61.1 out of 100 Growth Capital Valuation Relative
46. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) VIESL · breaking out · Too little evidence to rank firmly · 47% evidence 58.5 out of 100 Growth Capital Valuation Relative
47. [Q-Line Biotech Ltd](https://www.sectoralpha.in/stocks/q-line-biotech-ltd) QLINE · losing its lead · Too little evidence to rank firmly · 21% evidence 57.8 out of 100 Growth Capital Valuation Relative
48. Aayush Art and Bullion Ltd breaking out · Too little evidence to rank firmly · 48% evidence 57.1 out of 100 Growth Capital Valuation Relative
49. [HP Telecom India Ltd](https://www.sectoralpha.in/stocks/hp-telecom-india-ltd) HPTL · Too little evidence to rank firmly · 32% evidence 57.1 out of 100 Growth Capital Valuation Relative
50. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) quiet · Too little evidence to rank firmly · 43% evidence 55.9 out of 100 Growth Capital Valuation Relative
51. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) Too little evidence to rank firmly · 41% evidence 55.6 out of 100 Growth Capital Valuation Relative
52. Mardia Samyoung Capillary Tubes Company Ltd this page MSCTC · Too little evidence to rank firmly · 26% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.4/43.75 · Revenue 100% · Profit 100% · Operating margin change n/a · 24% evidence Capital efficiency 19.1/31.25 · ROCE 22.6% · Operating margin 15.3% · 57% evidence Valuation 10.8/25 · P/E 687× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 25.4 + 19.1 + 10.8 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 53. [Proventus Agrocom Ltd](https://www.sectoralpha.in/stocks/proventus-agrocom-ltd) PROV · breaking out · Too little evidence to rank firmly · 39% evidence 54.1 out of 100 Growth Capital Valuation Relative
54. [Pervasive Commodities Ltd](https://www.sectoralpha.in/stocks/pervasive-commodities-ltd) breaking out · Too little evidence to rank firmly · 48% evidence 51.8 out of 100 Growth Capital Valuation Relative
55. [Monika Alcobev Ltd](https://www.sectoralpha.in/stocks/monika-alcobev-ltd) MONIKA · Too little evidence to rank firmly · 27% evidence 49.9 out of 100 Growth Capital Valuation Relative
56. [Onix Solar Energy Ltd](https://www.sectoralpha.in/stocks/onix-solar-energy-ltd) ONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence 45.8 out of 100 Growth Capital Valuation Relative
57. Arvaya Healthcare Ltd ARVAYA · quiet · Too little evidence to rank firmly · 46% evidence 45.4 out of 100 Growth Capital Valuation Relative
58. [A-1 Ltd](https://www.sectoralpha.in/stocks/a-1-ltd) A1L · Too little evidence to rank firmly · 33% evidence 45.3 out of 100 Growth Capital Valuation Relative
59. [Satani Bearings Ltd](https://www.sectoralpha.in/stocks/satani-bearings-ltd) breaking out · Too little evidence to rank firmly · 42% evidence 42.9 out of 100 Growth Capital Valuation Relative
60. [Keto Motors Ltd](https://www.sectoralpha.in/stocks/keto-motors-ltd) quiet · Too little evidence to rank firmly · 42% evidence 40.9 out of 100 Growth Capital Valuation Relative
61. [Aerpace Industries Ltd](https://www.sectoralpha.in/stocks/aerpace-industries-ltd) breaking out · Too little evidence to rank firmly · 36% evidence 37.9 out of 100 Growth Capital Valuation Relative
62. [Prabhatam Infra Venture Ltd](https://www.sectoralpha.in/stocks/prabhatam-infra-venture-ltd) PRABHATAM · Too little evidence to rank firmly · 22% evidence 36.8 out of 100 Growth Capital Valuation Relative
63. [RRP Semiconductor Ltd](https://www.sectoralpha.in/stocks/rrp-semiconductor-ltd) RRP · Too little evidence to rank firmly · 42% evidence 34.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Trading](https://www.sectoralpha.in/sectors/trading), all 63 compared on one page. ## Which companies are close to Mardia Samyoung Capillary Tubes Company in size? Mardia Samyoung Capillary Tubes Company is the 32nd largest of 59 Trading companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Shiv Aum Steels, Prostarm Info Systems and Maxgrow India. Just below it: Yogi, Proventus Agrocom and Neueon Corporation. ### Trading companies close in size

1. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) ₹742 crore
2. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) ₹735 crore
3. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) ₹709 crore
4. Mardia Samyoung Capillary Tubes Company Ltd ₹707 crore
5. [Yogi Ltd](https://www.sectoralpha.in/stocks/yogi-ltd) ₹688 crore
6. [Proventus Agrocom Ltd](https://www.sectoralpha.in/stocks/proventus-agrocom-ltd) ₹670 crore
7. [Neueon Corporation Ltd](https://www.sectoralpha.in/stocks/neueon-corporation-ltd) ₹615 crore

[All 59 Trading companies, largest first](https://www.sectoralpha.in/sectors/trading#all-companies)

### Companies close in size in other industries

1. [Globe International Carriers Ltd](https://www.sectoralpha.in/stocks/globe-international-carriers-ltd) ₹421 crore · Transport - Road
2. [Magnus Steel & Infra Ltd](https://www.sectoralpha.in/stocks/magnus-steel-infra-ltd) ₹417 crore · Trading
3. Mardia Samyoung Capillary Tubes Company Ltd ₹413 crore
4. [Plastiblends India Ltd](https://www.sectoralpha.in/stocks/plastiblends-india-ltd) ₹413 crore · Plastics - Plastic & Plastic Products
5. [Forbes & Company Ltd](https://www.sectoralpha.in/stocks/forbes-company-ltd) ₹412 crore

## What else do people ask about Mardia Samyoung Capillary Tubes Company? ### What were Mardia Samyoung Capillary Tubes Company's latest quarterly results? Mardia Samyoung Capillary Tubes Company Ltd reported revenue of ₹12.3 Cr and net profit of ₹1.3 Cr for the Dec 2025 quarter. Earnings per share were ₹1.85. The operating margin was 15.3% (as of 30 October 2026). ### What is Mardia Samyoung Capillary Tubes Company's market cap? Mardia Samyoung Capillary Tubes Company Ltd's market capitalisation is ₹707 Cr at a share price of ₹51.94. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 30 October 2026). ### How is Mardia Samyoung Capillary Tubes Company performing? Mardia Samyoung Capillary Tubes Company Ltd's share price has been rising for 63 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 8 weeks running. This describes what the data did, not a rating (as of 30 October 2026). ### Will Mardia Samyoung Capillary Tubes Company's share price go up? This page does not forecast Mardia Samyoung Capillary Tubes Company Ltd's share price. What it shows instead: the share price is ₹51.94, and it has been rising for 63 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 30 October 2026). ### Who owns Mardia Samyoung Capillary Tubes Company? Promoters own 69.4% of Mardia Samyoung Capillary Tubes Company Ltd, foreign institutions , domestic institutions 0.1% and the public 30.5% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 30 October 2026). ### Where is Mardia Samyoung Capillary Tubes Company in its business cycle? Mardia Samyoung Capillary Tubes Company Ltd's FY24 operating margin was 407.1%, against a 5-year range of −150.8% to 4,000.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 15.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 30 October 2026). ### What could break the Mardia Samyoung Capillary Tubes Company story? Biggest thing to watch: the price has already been rising for 63 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 30 October 2026). ### Is Mardia Samyoung Capillary Tubes Company a stock worth studying right now? What the numbers show: Mardia Samyoung Capillary Tubes Company Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 30 October 2026). This is research, not advice. We’re not SEBI-registered.